221 related articles for article (PubMed ID: 24394867)
21. The effects of levodopa on word intelligibility in Parkinson's disease.
De Letter M; Santens P; Van Borsel J
J Commun Disord; 2005; 38(3):187-96. PubMed ID: 15748723
[TBL] [Abstract][Full Text] [Related]
22. Sequential changes in motor speech across a levodopa cycle in advanced Parkinson's disease.
De Letter M; Van Borsel J; Boon P; De Bodt M; Dhooge I; Santens P
Int J Speech Lang Pathol; 2010 Oct; 12(5):405-13. PubMed ID: 20602581
[TBL] [Abstract][Full Text] [Related]
23. Intrajejunal levodopa infusion in advanced Parkinson's disease: long-term effects on motor and non-motor symptoms and impact on patient's and caregiver's quality of life.
Fasano A; Ricciardi L; Lena F; Bentivoglio AR; Modugno N
Eur Rev Med Pharmacol Sci; 2012 Jan; 16(1):79-89. PubMed ID: 22338551
[TBL] [Abstract][Full Text] [Related]
24. Effect of levodopa on both verbal and motor representations of action in Parkinson's disease: a fMRI study.
Péran P; Nemmi F; Méligne D; Cardebat D; Peppe A; Rascol O; Caltagirone C; Demonet JF; Sabatini U
Brain Lang; 2013 Jun; 125(3):324-9. PubMed ID: 22841350
[TBL] [Abstract][Full Text] [Related]
25. Levodopa effect upon functional balance of Parkinson's disease patients.
Nova IC; Perracini MR; Ferraz HB
Parkinsonism Relat Disord; 2004 Oct; 10(7):411-5. PubMed ID: 15465397
[TBL] [Abstract][Full Text] [Related]
26. Effects of Levodopa on Vowel Articulation in Patients with Parkinson's Disease.
Okada Y; Murata M; Toda T
Kobe J Med Sci; 2015 Apr; 61(5):E144-54. PubMed ID: 27363398
[TBL] [Abstract][Full Text] [Related]
27. Quantitative study of salivary secretion in Parkinson's disease.
Tumilasci OR; Cersósimo MG; Belforte JE; Micheli FE; Benarroch EE; Pazo JH
Mov Disord; 2006 May; 21(5):660-7. PubMed ID: 16419045
[TBL] [Abstract][Full Text] [Related]
28. Orofacial Strength and Voice Quality as Outcome of Levodopa Challenge Test in Parkinson Disease.
Lechien JR; Delsaut B; Abderrakib A; Huet K; Delvaux V; Piccaluga M; Khalife M; Harmegnies B; Saussez S; Blecic S
Laryngoscope; 2020 Dec; 130(12):E896-E903. PubMed ID: 32239775
[TBL] [Abstract][Full Text] [Related]
29. Slowing of oscillatory brain activity is a stable characteristic of Parkinson's disease without dementia.
Stoffers D; Bosboom JL; Deijen JB; Wolters EC; Berendse HW; Stam CJ
Brain; 2007 Jul; 130(Pt 7):1847-60. PubMed ID: 17412733
[TBL] [Abstract][Full Text] [Related]
30. Pulmonary functions in Parkinson's disease.
Sathyaprabha TN; Kapavarapu PK; Pall PK; Thennarasu K; Raju TR
Indian J Chest Dis Allied Sci; 2005; 47(4):251-7. PubMed ID: 16255396
[TBL] [Abstract][Full Text] [Related]
31. Levodopa induced motor complications in Thai Parkinson's disease patients.
Kulkantrakorn K; Tiamkao S; Pongchaiyakul C; Pulkes T
J Med Assoc Thai; 2006 May; 89(5):632-7. PubMed ID: 16756048
[TBL] [Abstract][Full Text] [Related]
32. Folate and vitamin B12 levels in levodopa-treated Parkinson's disease patients: their relationship to clinical manifestations, mood and cognition.
Triantafyllou NI; Nikolaou C; Boufidou F; Angelopoulos E; Rentzos M; Kararizou E; Evangelopoulos ME; Vassilopoulos D
Parkinsonism Relat Disord; 2008; 14(4):321-5. PubMed ID: 18055246
[TBL] [Abstract][Full Text] [Related]
33. Levodopa influences striatal activity but does not affect cortical hyper-activity in Parkinson's disease.
Martinu K; Degroot C; Madjar C; Strafella AP; Monchi O
Eur J Neurosci; 2012 Feb; 35(4):572-83. PubMed ID: 22304628
[TBL] [Abstract][Full Text] [Related]
34. Instability of syllable repetition in Parkinson's disease--influence of levodopa and deep brain stimulation.
Skodda S; Flasskamp A; Schlegel U
Mov Disord; 2011 Mar; 26(4):728-30. PubMed ID: 21506151
[TBL] [Abstract][Full Text] [Related]
35. Fundamental frequency change during offset and onset of voicing in individuals with Parkinson disease.
Goberman AM; Blomgren M
J Voice; 2008 Mar; 22(2):178-91. PubMed ID: 16950600
[TBL] [Abstract][Full Text] [Related]
36. Polar-phase indices of perioral muscle reciprocity during syllable production in Parkinson's disease.
Chu SY; Barlow SM; Lee J; Wang J
Int J Speech Lang Pathol; 2017 Dec; 19(6):616-627. PubMed ID: 28425760
[TBL] [Abstract][Full Text] [Related]
37. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.
Talati R; Baker WL; Patel AA; Reinhart K; Coleman CI
Int J Clin Pract; 2009 Apr; 63(4):613-23. PubMed ID: 19222614
[TBL] [Abstract][Full Text] [Related]
38. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study.
Parkinson Study Group
Arch Neurol; 2005 Feb; 62(2):241-8. PubMed ID: 15710852
[TBL] [Abstract][Full Text] [Related]
39. Role of the pharmacist in the effective management of wearing-off in Parkinson's disease.
Simonson W; Hauser RA; Schapira AH
Ann Pharmacother; 2007 Nov; 41(11):1842-9. PubMed ID: 17878397
[TBL] [Abstract][Full Text] [Related]
40. Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson disease.
Olanow CW; Kieburtz K; Stern M; Watts R; Langston JW; Guarnieri M; Hubble J;
Arch Neurol; 2004 Oct; 61(10):1563-8. PubMed ID: 15477510
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
